Shuttle Pharmaceuticals Holdings Inc (SHPH)

$0.87 -0.16 (-15.91%)
Market Cap 5.59M
Revenue (ttm) 0.00
Net Income (ttm) -11.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 15,222,528
Avg Vol 382,096
Day's Range N/A - N/A
Shares Out 5.59M
Stochastic %K 80%
Beta -0.53
Analysts Strong Buy
Price Target N/A

Company Profile

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HD...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 240 403 4212
Address:
401 Professional Drive, Suite 260, Gaithersburg, United States
realditzy
realditzy May. 1 at 4:19 PM
$SHPH loaded 3,000 more shares @ 0.87 Not much but it’s something
1 · Reply
Khassab
Khassab May. 1 at 4:14 PM
$SHPH
0 · Reply
Roaring_Capybara
Roaring_Capybara May. 1 at 4:12 PM
$SHPH Bought the dip at 0.866.
1 · Reply
CantAffordMe
CantAffordMe May. 1 at 4:08 PM
$SHPH the diarrhea is strong with this one
1 · Reply
TheBlackRose
TheBlackRose May. 1 at 3:20 PM
Keep ticker AMS ✅on high watch, this can breakout any moment!! AMS has $28M revenue and trades at a $8.5M market cap. That’s 0.30x P/S. $FFIE had zero revenue when it ran 4,000%. Book value on AMSis $3.66 per share. Stock is at $1.6 . You are buying a dollar for 32 cents. I believe AMS can be the next big runner, best to be early bulls! $RDAC $SHPH $SMX $BYND ..qww3
0 · Reply
realditzy
realditzy May. 1 at 3:20 PM
$SHPH
0 · Reply
MegaTrade22
MegaTrade22 May. 1 at 3:17 PM
$SHPH
0 · Reply
Rvazstocksfl
Rvazstocksfl May. 1 at 2:57 PM
$SHPH see
0 · Reply
Rvazstocksfl
Rvazstocksfl May. 1 at 2:56 PM
$SHPH I told ya
0 · Reply
FinacialSuicide
FinacialSuicide May. 1 at 2:55 PM
$SHPH most likely it is going to spike on Monday when the deal closes!
0 · Reply
Latest News on SHPH
United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation

May 1, 2026, 8:41 AM EDT - 4 hours ago

United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation

Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner

Apr 30, 2026, 4:05 PM EDT - 21 hours ago

Shuttle Merges with United Dogecoin to Become the World's Largest Public Dogecoin Miner

RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Mar 27, 2026, 8:00 AM EDT - 5 weeks ago

RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Mar 26, 2026, 4:05 PM EDT - 5 weeks ago

Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public Offering

Mar 12, 2026, 8:30 AM EDT - 7 weeks ago

E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals' $3.5 Million Public Offering

Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

Mar 6, 2026, 8:00 AM EST - 2 months ago

Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever

Jan 13, 2026, 4:00 PM EST - 3 months ago

Utah Approves AI Prescriptions Drugs. How AI Is Saving Time, Cutting Costs - and Why Molecule.ai's Drug Discovery Platform Matters More Than Ever

Shuttle Pharmaceuticals Acquires AI Health Platform

Nov 21, 2025, 9:30 AM EST - 5 months ago

Shuttle Pharmaceuticals Acquires AI Health Platform

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Nov 3, 2025, 7:00 AM EST - 6 months ago

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Oct 22, 2025, 10:00 AM EDT - 6 months ago

Shuttle Pharma and the Moment Science Learned to Think for Itself (NASDAQ:SHPH)

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Oct 22, 2025, 7:00 AM EDT - 6 months ago

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Oct 21, 2025, 5:55 PM EDT - 6 months ago

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Oct 21, 2025, 4:05 PM EDT - 6 months ago

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Shuttle Executes LOI with Molecule.ai

Oct 10, 2025, 10:20 AM EDT - 7 months ago

Shuttle Executes LOI with Molecule.ai

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Oct 9, 2025, 4:15 PM EDT - 7 months ago

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Aug 14, 2025, 4:05 PM EDT - 9 months ago

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Jun 24, 2025, 4:10 PM EDT - 11 months ago

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Jun 20, 2025, 3:55 PM EDT - 11 months ago

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Jun 12, 2025, 12:00 PM EDT - 11 months ago

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Jun 12, 2025, 8:30 AM EDT - 11 months ago

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Jun 4, 2025, 4:01 PM EDT - 11 months ago

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Shuttle Pharma Provides Corporate Update

May 15, 2025, 4:45 PM EDT - 1 year ago

Shuttle Pharma Provides Corporate Update

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

May 8, 2025, 4:01 PM EDT - 1 year ago

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Apr 21, 2025, 4:15 PM EDT - 1 year ago

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Apr 10, 2025, 4:01 PM EDT - 1 year ago

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Mar 13, 2025, 4:10 PM EDT - 1 year ago

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Mar 12, 2025, 9:24 AM EDT - 1 year ago

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Mar 12, 2025, 6:20 AM EDT - 1 year ago

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Feb 26, 2025, 10:45 AM EST - 1 year ago

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 7, 2025, 9:00 AM EST - 1 year ago

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Nov 26, 2024, 9:00 AM EST - 1 year ago

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Nov 13, 2024, 5:00 PM EST - 1 year ago

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 29, 2024, 9:05 PM EDT - 1 year ago

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Oct 28, 2024, 4:05 PM EDT - 1 year ago

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 16, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Sep 4, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Aug 26, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Aug 14, 2024, 4:10 PM EDT - 1 year ago

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Jun 18, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 22, 2024, 4:15 PM EDT - 2 years ago

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Shuttle Pharma Provides First Quarter 2024 Corporate Update

May 14, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharma Provides First Quarter 2024 Corporate Update

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Apr 23, 2024, 4:15 PM EDT - 2 years ago

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Apr 3, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Mar 22, 2024, 9:00 AM EDT - 2 years ago

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Mar 5, 2024, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Feb 13, 2024, 8:00 AM EST - 2 years ago

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 23, 2024, 4:30 PM EST - 2 years ago

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jan 8, 2024, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Dec 11, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

realditzy
realditzy May. 1 at 4:19 PM
$SHPH loaded 3,000 more shares @ 0.87 Not much but it’s something
1 · Reply
Khassab
Khassab May. 1 at 4:14 PM
$SHPH
0 · Reply
Roaring_Capybara
Roaring_Capybara May. 1 at 4:12 PM
$SHPH Bought the dip at 0.866.
1 · Reply
CantAffordMe
CantAffordMe May. 1 at 4:08 PM
$SHPH the diarrhea is strong with this one
1 · Reply
TheBlackRose
TheBlackRose May. 1 at 3:20 PM
Keep ticker AMS ✅on high watch, this can breakout any moment!! AMS has $28M revenue and trades at a $8.5M market cap. That’s 0.30x P/S. $FFIE had zero revenue when it ran 4,000%. Book value on AMSis $3.66 per share. Stock is at $1.6 . You are buying a dollar for 32 cents. I believe AMS can be the next big runner, best to be early bulls! $RDAC $SHPH $SMX $BYND ..qww3
0 · Reply
realditzy
realditzy May. 1 at 3:20 PM
$SHPH
0 · Reply
MegaTrade22
MegaTrade22 May. 1 at 3:17 PM
$SHPH
0 · Reply
Rvazstocksfl
Rvazstocksfl May. 1 at 2:57 PM
$SHPH see
0 · Reply
Rvazstocksfl
Rvazstocksfl May. 1 at 2:56 PM
$SHPH I told ya
0 · Reply
FinacialSuicide
FinacialSuicide May. 1 at 2:55 PM
$SHPH most likely it is going to spike on Monday when the deal closes!
0 · Reply
MajorGainz7
MajorGainz7 May. 1 at 2:38 PM
$SHPH whats milestones to issue shares? $2+++ ?
1 · Reply
realditzy
realditzy May. 1 at 2:36 PM
$SHPH not worried 🥱
1 · Reply
Ataifanboymentalhealthz
Ataifanboymentalhealthz May. 1 at 2:27 PM
$SHPH when bought at the top?
1 · Reply
mmstk23
mmstk23 May. 1 at 2:23 PM
$SHPH F##k
0 · Reply
Big79979
Big79979 May. 1 at 2:14 PM
$SHPH If management decides to get into Dogecoin, Elon Musk would think it's pretty hilarious. Though right now he's busy suing OpenAI, hahaha 😂
0 · Reply
P_etheris
P_etheris May. 1 at 1:13 PM
$CUE $SHPH How will this fly with 32M shares shareholders and 112M warrants??? THIS WILL DROP TO SMITHEREENS 🤦🏻‍♂️😅 Read the filing tard🚨
1 · Reply
321rip
321rip May. 1 at 1:12 PM
$SHPH sharp pre mkt p/b off yest. HI = a retest of gap up/load da boat
0 · Reply
TheBlackRose
TheBlackRose May. 1 at 1:11 PM
Small cap is starting to wake up, look at what AKAN and CUE did! If you are looking for the next Monster runner, check out AMS 🚨 AMS very small float as well and is Primed for take off! I believe AMS has a chance to see a parabolic run, keep on high watch! $SHPH $CHSN $CTNT $YCBD W6.
0 · Reply
TheBlackRose
TheBlackRose May. 1 at 1:11 PM
Small cap is starting to wake up, look at what AKAN and CUE did! If you are looking for the next Monster runner, check out AMS 🚨 AMS very small float as well and is Primed for take off! I believe AMS has a chance to see a parabolic run, keep on high watch! $AIXI $ATXG $SST $SHPH ..wwa1
1 · Reply
Josema66
Josema66 May. 1 at 1:10 PM
$SHPH Great news here, this will fly! $CUE
0 · Reply
focafoca99
focafoca99 May. 1 at 1:07 PM
$SHPH agreed to merge with United Dogecoin in a deal backed by an $11 million PIPE that aims to build a scaled DOGE mining platform.
0 · Reply
NYChichas
NYChichas May. 1 at 1:02 PM
$SHPH $0.93-0.95.?
0 · Reply